शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEFabino Enterprises Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 13 Nov, 2025 · 18:16 IST

Results- Financial results for the Half Year ended September 30, 2025

Revenue declinedNet loss reportedResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Fabino Enterprises reported weak H1 FY26 results, with standalone net sales collapsing to just ₹67.99 lakhs from ₹425.12 lakhs in H1 FY25 — an 84% year-on-year decline. The company slipped into a standalone net loss of ₹24.87 lakhs (EPS of -₹1.18) versus a small profit of ₹4.65 lakhs a year ago. On a consolidated basis, revenue rose about 56% YoY to ₹663.34 lakhs, helped by the newly consolidated subsidiary Upender Metaplast Pvt Ltd, but the group still posted a net loss of ₹18.59 lakhs. Total expenses (₹107.13 lakhs standalone) exceeded revenues, squeezing margins. The balance sheet shows reserves declining to ₹194.03 lakhs (from ₹218.90 lakhs) and long-term borrowings slightly rising to ₹163.52 lakhs. Operating cash flow remained marginally positive at ₹5.10 lakhs standalone.

Likely market impact

Sharply negative for shareholders — the standalone business is in clear contraction with a swing from profit to loss, though the consolidated figures get a boost from the subsidiary. Expect weak sentiment around the SME-listed stock given the steep revenue fall and negative earnings.